Committee for Medicinal Products for Human Use (CHMP) recommends approval of osilodrostat (Isturisa) for treatment of Cushing's syndrome
European Medicines Agency - EMA
European Medicines Agency
15 November 2019
Osilodrostat inhibits 11-beta-hydroxylase (CYP11B1), an enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. The expected benefits include the ability to control or normalise raised cortisol levels in adults.